Effects of aggressive lipid-lowering therapy in patients with glomerulonephritis

Effects of aggressive lipid-lowering therapy in patients with glomerulonephritis - Statin therapy for glomerulonephritis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000005392

Enrollment

Registered

2011-04-11

Start date

2011-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

glomerulonephritis

Interventions

Administration of statins No administration of statins

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients with glomerulonephritis 2) Patients with lipid disorder (LDL-C of 100 mg/dl or more)

Exclusion criteria

Exclusion criteria: 1) Allergy against statins 2) Pregnant 3) Patients judged as being inappropriate for this study by investigators

Design outcomes

Primary

Measure	Time frame
Changes in urinary protein Changes in eGFR Changes in ADMA and endothelial lipase	—

Secondary

Measure	Time frame
Serum lipid profile (Total cholesterol,LDL cholesterol, triglyceride) , apolipoprotein, and high-sensitive CRP	—

Countries

Japan

Contacts

Public ContactKentaro Nakai

Kobe University School of Medicine Division of Nephrology & Kidney Center

kentaro-kyu@umin.org078-382-6500

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026